Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | TTR | P02766 | 2/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 5/20 | 0.40 |
| ▸ | BACE1 | P56817 | 2/20 | 0.39 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14743799 | 0.88 | ESR1 (0.44) | ESR1TTRAPPNR1H4TUBB1 | |
| SCHEMBL6059676 | 0.88 | PTGS2 (0.49) | ESR1TTRAPPNR1H4BACE1 | |
| SCHEMBL6059677 | 0.88 | PTGS2 (0.49) | ESR1TTRAPPNR1H4BACE1 | |
| SCHEMBL18323018 | 0.85 | ESR1 (0.42) | ESR1TTRAPPNR1H4TUBB1 | |
| SCHEMBL16486855 | 0.85 | ESR1 (0.42) | ESR1TTRAPPNR1H4TUBB1 | |
| SCHEMBL13660708 | 0.84 | TUBB1 (0.46) | ESR1TTRAPPNR1H4TUBB1 | |
| SCHEMBL2847487 | 0.83 | TTR (0.59) | TTRAPPBACE1TUBB1PTPN1 | |
| SCHEMBL2847488 | 0.83 | TTR (0.59) | TTRAPPBACE1TUBB1PTPN1 | |
| SCHEMBL38657985 | 0.82 | ALOX5 (0.40) | ESR1NR1H4TUBB1CSF1RHDAC1 | |
| SCHEMBL20064785 | 0.81 | NR1H4 (0.42) | ESR1TTRAPPNR1H4TUBB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110130445-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-02 | — | — | US | disclosed |
| US-20110130445-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130445-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | FABP3, PC, PAH | ESR1 3446/4885TTR 481/4885APP 1156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.